LAB — Standard BioTools Share News
0.000.00%
Last trade - 00:00- $258.47m
- -$217.95m
- $85.33m
Standard BioTools Inc reports results for the quarter ended in December - Earnings Summary
Standard BioTools Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Standard BioTools And Next Gen Diagnostics Announce Partnership
Brief: Standard BioTools Reports Prelim Q4 and Full Year 2023 Revenue
Brief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders
Brief: Somalogic Issued Statement In Response To Press Release By Madryn Asset Management
Brief: Madryn Asset Management Says Sends Letter To ISS Requesting It Withdraw “Cautionary Support” For Somalogic’S Proposed Merger With Standard BioTools
Brief: Tikvah Management Announces Intention To Vote Against Somalogic's Proposed Merger With Standard Biotools
Brief: Madryn Asset Management Highlights Conflicts Of Interest Related To Proposed Somalogic Merger With Standard Biotools
Brief: SomaLogic Issues Letter To Stockholders Reiterating Recommendation For Value Maximizing Merger With Standard BioTools
Brief: Skye Fund Iii Issued An Open Letter To Somalogic, Inc., Shareholders
Brief: Madryn Asset Management Urges All Somalgic Shareholders To Vote "Against" Deal With Standard Biotools, To Send Green Proxy Card
Brief: Standard BioTools And SomaLogic Announce Date For Special Meetings Of Stockholders To Vote On Proposed Merger
Brief: Standard BioTools Q3 net income USD -21 million
Standard BioTools Inc expected to post a loss of 12 cents a share - Earnings Preview
SomaLogic up on all-stock merger with Standard BioTools
Brief: Standard Biotools Upon Termination Of Deal, Co May Be Required To Pay Somalogic Fee Of $19.1 Million And/Or Reimburse Somalogic's Expenses Up To $2 Million
Brief: Standard Biotools And Somalogic To Combine In All-Stock Merger